Residents of the Tri-State area can look forward to updated COVID-19 vaccinations shortly following an announcement that the U.S. Food and Drug Administration (FDA) has approved shots from Pfizer and Moderna targeting the KP.2 variant. This specific strain has been causing a rise in COVID-19 cases through the summer, notably in Ohio. Local12 reports that these vaccinations are not just boosters but new inoculations explicitly designed to combat the emerging threat of the KP.2 variant.
According to the same source, Doctor Stephen Feagins emphasized the importance of coinciding with the updated vaccine with the seasonal flu shot, although they serve different purposes. The FDA has responded proactively to SARS-CoV-2's mutations, advising manufacturers as early as June that the COVID-19 vaccines for the 2024-2025 season should include a monovalent JN.1 vaccine. However, due to the prevalence and the potential risk posed by the KP.2 strain, it has since revised its recommendation, instructing manufacturers that the vaccine should focus on this strain if feasible.
Coupled with emergency use authorization, this approval catalyzes the distribution of the updated vaccines, purported to offer heightened protection against the virus, particularly severe outcomes including hospitalization and death. The FDA's press release obtained by FDA Official News detailed these expansions to the emergency use of the mRNA COVID-19 vaccines produced by ModernaTX Inc. and Pfizer Inc., fitting the new virulent profile of the KP.2 strain.
_D.jpg){kind=link}